Clinical trials: Patients with Multiple Sclerosis
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
RRMS
Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece
This is a non interventional, multicenter clinical trial, in adult patients receiving Tecfidera per approved SmPC and routine clinical practice.
- Trial name
- FIDELITY (NCT03101735)
- Testing
- Dimethyl Fumarate (DMF)
- Where
- Greece
- Volunteers
- 455 people
- Sponsor
- Genesis Pharma CNS & Specialty
Multiple Sclerosis, Relapsing-remitting
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with…
- Trial name
- ADHERQOL (NCT02394782)
- Testing
- RebiSmart®2.0, MSdialog™
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Primary Objective: To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing forms of multiple sclerosis as compared with baseline values and those of a reference population of untreated healthy…
- Trial name
- TERI-DYNAMIC (NCT01863888)
- Testing
- teriflunomide HMR1726, cholestyramine, charcoal
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanofi
Relapsing Remitting Multiple Sclerosis
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01963611
- Testing
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg
- Where
- 118 sites in United States, Bulgaria and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period
The aim of the SEPLUS study is to evaluate the patients characteristics associated with adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in the BetaPlus program
- Trial name
- SEPLUS (NCT01076595)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Bayer
Multiple Sclerosis
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
- Trial name
- NCT01610700
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Muscle Spasticity
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes: 1. To determine whether AV650 is safe for patients with multiple sclerosis; 2.
- Trial name
- NCT00532532
- Testing
- tolperisone HCl
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Avigen
Multiple Sclerosis
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
Study Title: A Serologic Study to Correlate b-IFN NAb titers to b-IFN Induced Biomarker Response in Patients with Multiple Sclerosis Objectives: Subjects currently on any of the three b-IFN preparations (Avonex (Interferon b-1a…
- Trial name
- NCT00288990
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
Multiple sclerosis is a chronic autoimmune, inflammatory neurological disease of the central nervous system. It is the most common disabling neurologic disease of young people.
- Trial name
- NCT03283397
- Testing
- EK-12, INF beta-1a
- Where
- Turkey (Türkiye)
- Volunteers
- 301 people
- Sponsor
- Bosnalijek D.D
Relapsing Multiple Sclerosis
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.
- Trial name
- NCT01127750
- Testing
- FTY720
- Where
- 289 sites in Australia, Austria and 21 more
- Volunteers
- 2,417 people
- Sponsor
- Novartis
Multiple Sclerosis
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).
- Trial name
- NCT00103974
- Testing
- BHT-3009-01
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bayhill Therapeutics
Amyotrophic Lateral Sclerosis
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects…
- Trial name
- NCT05981040
- Testing
- ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
- Where
- 7 sites in India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Multiple Sclerosis
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body.
- Trial name
- NCT07826689
- Testing
- PRO-1562 Oral Capsules
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Progentos Therapeutics
Secondary Progressive Multiple Sclerosis
A Study for Patients With Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.
- Trial name
- MAESTRO-01 (NCT00869726)
- Testing
- dirucotide
- Where
- 10 sites in Canada, Denmark and 8 more
- Volunteers
- 596 people
- Sponsor
- Eli Lilly and Company
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals